Open in Screener

CRNX

Crinetics Pharmaceuticals Inc

Oct 03 • 04:00PM ET

40.86

-0.65 -1.57 %

Healthcare • Biotechnology • USA • NASD

Peers: NBIX LLY PFE NVS BMRN VRTX REGN SNY MRK BMY

| Held by: VTI IWM VB VBK IWO VXF IBB SCHA VTWO IHE

Index	RUT	P/E	-	EPS (ttm)	-4.11	Insider Own	7.54%	Shs Outstand	94.13M	Perf Week	-11.00%
Market Cap	3.85B	Forward P/E	-	EPS next Y	-5.01	Insider Trans	-2.26%	Shs Float	87.08M	Perf Month	19.30%
Enterprise Value	2.70B	PEG	-	EPS next Q	-1.25	Inst Own	107.71%	Short Float	16.94%	Perf Quarter	40.61%
Income	-369.83M	P/S	2768.37	EPS this Y	-29.43%	Inst Trans	3.14%	Short Ratio	11.57	Perf Half Y	41.53%
Sales	1.39M	P/B	3.28	EPS next Y	-5.00%	ROA	-33.24%	Short Interest	14.75M	Perf YTD	-20.09%
Book/sh	12.45	P/C	3.22	EPS next 5Y	-2.29%	ROE	-36.94%	52W High	62.53 -34.66%	Perf Year	-21.30%
Cash/sh	12.71	P/FCF	-	EPS past 3/5Y	-9.67% -12.11%	ROIC	-30.44%	52W Low	24.10 69.54%	Perf 3Y	105.43%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-1.22% -	Gross Margin	-147.27%	Volatility	5.21% 5.31%	Perf 5Y	177.58%
Dividend TTM	-	EV/Sales	1943.24	EPS Y/Y TTM	-9.10%	Oper. Margin	-30392.17%	ATR (14)	2.21	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	17.80	Sales Y/Y TTM	-100.00%	Profit Margin	-26568.53%	RSI (14)	62.06	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	17.80	EPS Q/Q	-31.54%	SMA20	10.20%	Beta	0.25	Target Price	80.27
Payout	-	Debt/Eq	0.04	Sales Q/Q	-	SMA50	24.25%	Rel Volume	1.09	Prev Close	41.51
Employees	437	LT Debt/Eq	0.04	Earnings	Aug 07 AMC	SMA200	18.27%	Avg Volume	1.27M	Price	40.86
IPO	Jul 18, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-13.73% 68.00%	Trades		Volume	1,384,663	Change	-1.57%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-25	Initiated	Goldman	Neutral	$36
Mar-25-25	Initiated	Stifel	Buy	$60
Feb-11-25	Initiated	TD Cowen	Buy
Feb-04-25	Initiated	Wolfe Research	Peer Perform
Jan-22-25	Upgrade	Jefferies	Hold → Buy	$55
Mar-06-24	Initiated	Citigroup	Buy	$68
Jan-16-24	Initiated	Morgan Stanley	Overweight	$50
Dec-21-23	Initiated	Jefferies	Hold	$35
Nov-20-23	Resumed	JP Morgan	Overweight	$35
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$52 → $50
Aug-31-23	Initiated	Oppenheimer	Outperform	$40
Apr-24-23	Initiated	Piper Sandler	Overweight	$56
Mar-30-23	Initiated	Robert W. Baird	Outperform	$48
Nov-30-21	Initiated	JMP Securities	Mkt Outperform	$43
Nov-23-21	Initiated	Evercore ISI	Outperform	$68
Jun-18-21	Upgrade	JP Morgan	Neutral → Overweight	$28
Dec-23-19	Initiated	ROTH Capital	Buy	$37
Feb-14-19	Initiated	H.C. Wainwright	Buy	$35
Aug-13-18	Initiated	Piper Jaffray	Overweight	$40
Aug-13-18	Initiated	Leerink Partners	Outperform	$43

Show Previous Ratings

Sep-30-25 11:49AM	JMP Backs Crinetics Pharmaceuticals, Inc. (CRNX) With Big Upside Post-Approval (Insider Monkey)
04:01AM	JPMorgan Lifts PT on Crinetics Pharmaceuticals (CRNX) to $52 From $53, Keeps an Overweight Rating (Insider Monkey)
Sep-29-25 06:54PM	Crinetics Pharma (CRNX) Flies 35% Higher on FDA Approval of Acromegaly Drug (Insider Monkey) -5.23%
Sep-28-25 08:30AM	Is Crinetics Pharmaceuticals Stock a Buy? (Motley Fool)
Sep-26-25 04:22PM	Crinetics Pharma Surges After FDA OKs Its Treatment For Growth Disorder (Investor's Business Daily) +27.92% -5.23%
01:07PM	Loading…
01:07PM	FDA Approves Crinetics Pharma's First Daily Pill For Rare Growth Disorder (Benzinga)
09:14AM	Crinetics Pharma Surges After FDA OKs Its Treatment For A Form Of Gigantism (Investor's Business Daily)
Sep-25-25 05:30PM	Crinetics Announces FDA Approval of PALSONIFY (paltusotine) for the Treatment of Adults with Acromegaly (GlobeNewswire)
Sep-10-25 04:30PM	Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:21PM	CTSWC25: The future of clinical trial supply hinges on risk management (Clinical Trials Arena)
Aug-21-25 08:45AM	Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH) (GlobeNewswire)
Aug-11-25 04:05PM	Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-07-25 05:55PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-25 11:56AM	Crinetics Pharmaceuticals, Inc. (CRNX)' Oral Acromegaly Drug Nears FDA Decision After Strong Phase 3 Data (Insider Monkey)
10:00AM	Loading…
10:00AM	Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline (Zacks)
Jul-16-25 09:38AM	Crinetics Pharmaceuticals (CRNX) Gets Initiated With a Hold Rating at Goldman Sachs (Insider Monkey)
Jul-14-25 05:53AM	Crinetics reveals new data from acromegaly therapy programme (Clinical Trials Arena)
Jul-13-25 05:45PM	Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY (Paltusotine) in Acromegaly at ENDO 2025 (GlobeNewswire)
Jul-11-25 08:00AM	Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jul-10-25 04:28PM	Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-08-25 08:21AM	Should You Hold Crinetics Pharmaceuticals (CRNX)? (Insider Monkey)
Jul-03-25 08:17AM	Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last? (Zacks)
Jun-30-25 04:05PM	Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline (GlobeNewswire)
Jun-16-25 08:00AM	Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025 (GlobeNewswire)
Jun-10-25 04:29PM	Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-23-25 08:00AM	Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025 (GlobeNewswire)
May-15-25 04:05PM	Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025 (GlobeNewswire)
May-12-25 04:05PM	Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.60% -7.11%
May-09-25 01:01PM	Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings Call Highlights: Strategic Growth and ... (GuruFocus.com) -6.18%
08:48AM	Loading…
08:48AM	Is Crinetics Pharmaceuticals, Inc. (CRNX) The Best Stock That Will Bounce Back? (Insider Monkey)
May-08-25 05:40PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-07-25 09:57AM	What To Expect From Crinetics Pharmaceuticals Inc (CRNX) Q1 2025 Earnings (GuruFocus.com)
Apr-11-25 08:00AM	Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire) +8.42%
Apr-10-25 05:04PM	Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-25 02:15PM	Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA (Seeking Alpha)
Mar-27-25 04:05PM	Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly (GlobeNewswire)
Mar-10-25 04:36PM	Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-25 04:05PM	Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) +7.74%
03:24PM	Is Crinetics Pharmaceuticals (CRNX) the Worst Performing Mid Cap Stock to Buy According to Analysts? (Insider Monkey)
Feb-26-25 07:26AM	What To Expect From Crinetics Pharmaceuticals Inc (CRNX) Q4 2024 Earnings (GuruFocus.com)
Feb-24-25 08:30AM	Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer (GlobeNewswire) -7.58%
Feb-20-25 04:05PM	Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences (GlobeNewswire)
Feb-10-25 04:44PM	Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-06-25 04:35PM	Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 (GlobeNewswire)
Feb-05-25 04:57PM	Crinetics Pharmaceuticals, Inc. (CRNX): One of Januarys Biggest Losers (Insider Monkey)
Jan-29-25 05:37PM	What Are Analysts Talking About Crinetics Pharmaceuticals (CRNX)? (Insider Monkey)
Jan-21-25 04:10PM	Is Crinetics Pharmaceuticals (CRNX) Among Billionaire Joseph Edelmans Long-Term Stock Picks? (Insider Monkey)
Jan-17-25 11:12AM	Crinetics Pharmaceuticals, Inc. (CRNX): The Biotech Stock with Biggest Upside Potential (Insider Monkey)
Jan-10-25 05:15PM	Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -16.31%
07:00AM	Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) (GlobeNewswire)
Jan-06-25 08:00AM	Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.00%
Dec-16-24 08:00AM	Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer (GlobeNewswire)
Dec-10-24 08:44PM	Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.21%
06:22AM	FDA accepts Crinetics Pharmaceuticals' NDA for acromegaly treatment therapy (Pharmaceutical Business Review)
Dec-09-24 08:00AM	Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly (GlobeNewswire)
Nov-15-24 09:00AM	Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences (GlobeNewswire) -8.28%
Nov-14-24 04:05PM	UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting (GlobeNewswire)
Nov-13-24 02:18AM	Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Nov-12-24 04:07PM	Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting (GlobeNewswire)
04:05PM	Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-11-24 04:05PM	Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-17-24 03:09PM	State Street Corp's Strategic Acquisition in Crinetics Pharmaceuticals (GuruFocus.com)
Oct-16-24 08:00AM	Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024 (GlobeNewswire)
Oct-10-24 04:40PM	Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:57AM	Morning Movers: Arcadium Lithium surges after deal to be acquired (TipRanks)
Oct-09-24 05:56PM	Crinetics Pharmaceuticals Inc (CRNX) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Oct-08-24 11:55PM	Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire)
04:01PM	Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Sep-26-24 04:05PM	Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly (GlobeNewswire)
Sep-12-24 07:00PM	Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ... (GuruFocus.com) +5.02%
Sep-10-24 04:40PM	Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-24 01:07AM	Crinetics Pharmaceuticals, Inc. (CRNX): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 04:05PM	Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-28-24 07:01PM	Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ... (GuruFocus.com)
Aug-14-24 07:02PM	Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ... (GuruFocus.com)
Aug-12-24 04:05PM	Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-24 09:57PM	CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace) +5.05% -6.11%
06:00PM	Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
08:30AM	Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges (GlobeNewswire)
Aug-01-24 10:01AM	Crinetics Pharmaceuticals, Inc. (CRNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-26-24 07:00PM	Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ... (GuruFocus.com)
Jul-18-24 04:05PM	Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024 (GlobeNewswire)
Jul-12-24 07:01PM	Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ... (GuruFocus.com)
Jul-10-24 07:29PM	Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.33%
Jun-26-24 07:00PM	Insider Sale: Chief Scientific Officer Stephen Betz Sells Shares of Crinetics Pharmaceuticals ... (GuruFocus.com) -5.97%
02:11PM	7 Biotech Stocks to Boost Your Portfolio to Peak Health (InvestorPlace)
Jun-18-24 04:30PM	EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year 2024 Pacific Southwest Award Winner (GlobeNewswire)
Jun-12-24 02:38AM	Insider Sale at Crinetics Pharmaceuticals Inc (CRNX): Chief Scientific Officer Stephen Betz ... (GuruFocus.com) +6.60%
Jun-10-24 06:35PM	Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-24 12:16PM	Crinetics Unveils 'Stunning' Results In Highly Anticipated Study (Investor's Business Daily)
12:00PM	Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly (GlobeNewswire)
12:00PM	Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing's Syndrome (ADCS) (GlobeNewswire)
May-31-24 02:46AM	Insider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ... (GuruFocus.com)
May-30-24 04:05PM	Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs (GlobeNewswire)
May-22-24 08:00AM	Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts (GlobeNewswire)
May-16-24 05:23PM	Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake (Investopedia)

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pizzuti Dana	Chief Med and Dev Officer	Oct 01 '25	Option Exercise	16.89	5,000	84,450	71,270	Oct 03 04:41 PM
Pizzuti Dana	Chief Med and Dev Officer	Oct 01 '25	Sale	41.81	5,000	209,050	66,270	Oct 03 04:41 PM
DANA PIZZUTI	Officer	Oct 01 '25	Proposed Sale	41.65	5,000	208,250		Oct 01 04:30 PM
Struthers Richard Scott	President & CEO	Sep 26 '25	Sale	45.00	4,000	180,000	106,000	Sep 30 04:42 PM
Fust Matthew K	Director	Sep 26 '25	Option Exercise	1.91	10,000	19,100	38,836	Sep 30 04:41 PM
Fust Matthew K	Director	Sep 26 '25	Sale	44.75	16,000	716,000	22,836	Sep 30 04:41 PM
MATTHEW K FUST	Director	Sep 26 '25	Proposed Sale	35.89	16,000	574,240		Sep 26 04:27 PM
Struthers Richard Scott	Officer	Sep 26 '25	Proposed Sale	45.00	4,000	180,000		Sep 26 04:09 PM
Pizzuti Dana	Chief Med and Dev Officer	Sep 02 '25	Option Exercise	16.89	5,000	84,450	101,270	Sep 04 04:30 PM
Pizzuti Dana	Chief Med and Dev Officer	Sep 02 '25	Sale	32.10	5,000	160,500	96,270	Sep 04 04:30 PM
DANA PIZZUTI	Officer	Sep 02 '25	Proposed Sale	30.99	5,000	154,950		Sep 02 04:41 PM
Pizzuti Dana	Chief Med and Dev Officer	Aug 22 '25	Option Exercise	16.89	30,000	506,700	96,270	Aug 26 04:30 PM
Pizzuti Dana	Chief Med and Dev Officer	Aug 22 '25	Sale	30.43	30,000	912,900	66,270	Aug 26 04:30 PM
DANA PIZZUTI	Officer	Aug 22 '25	Proposed Sale	29.40	30,000	882,000		Aug 22 04:44 PM
Pizzuti Dana	Chief Med and Dev Officer	Aug 20 '25	Sale	29.18	6,492	189,437	66,270	Aug 21 04:30 PM
DANA PIZZUTI	Officer	Aug 20 '25	Proposed Sale	29.43	6,492	191,060		Aug 20 04:24 PM
Betz Stephen F.	Chief Scientific Officer	Jun 12 '25	Option Exercise	3.30	88,170	291,078	197,196	Jun 16 04:48 PM
Betz Stephen F.	Chief Scientific Officer	Jun 12 '25	Sale	32.23	97,483	3,141,877	99,713	Jun 16 04:48 PM
STEPHEN BETZ	Officer	Jun 12 '25	Proposed Sale	32.33	97,483	3,151,625		Jun 12 04:19 PM
Struthers Richard Scott	President & CEO	Apr 02 '25	Option Exercise	1.91	81,270	155,226	410,417	Apr 04 04:30 PM
Pizzuti Dana	Chief Med and Dev Officer	Mar 19 '25	Sale	34.20	2,515	86,021	72,233	Mar 21 06:34 PM
Knight Jeff E.	Chief Operating Officer	Mar 19 '25	Sale	34.20	7,162	244,964	87,491	Mar 21 06:33 PM
Betz Stephen F.	Chief Scientific Officer	Mar 19 '25	Sale	34.20	5,770	197,353	108,588	Mar 21 06:32 PM
Struthers Richard Scott	President & CEO	Mar 19 '25	Sale	34.20	17,338	593,017	329,147	Mar 21 06:31 PM
Pizzuti Dana	Chief Med and Dev Officer	Feb 03 '25	Option Exercise	16.89	5,000	84,450	36,748	Feb 05 04:30 PM
Pizzuti Dana	Chief Med and Dev Officer	Feb 03 '25	Sale	39.07	5,000	195,350	31,748	Feb 05 04:30 PM
DANA J PIZZUTI	Officer	Feb 03 '25	Proposed Sale	39.07	5,000	195,372		Feb 03 04:11 PM
Pizzuti Dana	Chief Med and Dev Officer	Jan 03 '25	Option Exercise	16.89	15,000	253,350	44,248	Jan 07 04:30 PM
Pizzuti Dana	Chief Med and Dev Officer	Jan 07 '25	Option Exercise	19.64	2,500	49,100	31,748	Jan 07 04:30 PM
Pizzuti Dana	Chief Med and Dev Officer	Jan 03 '25	Sale	52.09	15,000	781,350	29,248	Jan 07 04:30 PM
DANA J PIZZUTI	Officer	Jan 03 '25	Proposed Sale	52.09	15,000	781,323		Jan 03 04:12 PM
Betz Stephen F.	Chief Scientific Officer	Dec 16 '24	Option Exercise	1.91	2,331	4,452	71,358	Dec 18 04:30 PM
Struthers Richard Scott	President & CEO	Dec 02 '24	Sale	57.57	10,000	575,700	100,000	Dec 04 04:30 PM
Struthers Richard Scott	Officer	Dec 02 '24	Proposed Sale	57.27	10,000	572,700		Dec 02 04:06 PM
Knight Jeff E.	Chief Operating Officer	Nov 22 '24	Sale	56.52	501	28,317	51,653	Nov 26 04:30 PM

Open in Screener

NMRA

Neumora Therapeutics Inc

Oct 03 • 04:00PM ET

1.83

+0.05 2.81 %

Healthcare • Biotechnology • USA • NASD

NMRA Neumora Therapeutics Inc daily Stock Chart

Peers: BIIB VRTX NBIX AXSM ACAD SAGE ALKS BHVN PRTA AVXL

| Held by: VTI VXF SCHA IBB PRFZ VHT SCHB BTEC IBBQ MSSM

Index	-	P/E	-	EPS (ttm)	-1.57	Insider Own	66.51%	Shs Outstand	161.95M	Perf Week	5.17%
Market Cap	296.36M	Forward P/E	-	EPS next Y	-1.01	Insider Trans	0.00%	Shs Float	54.24M	Perf Month	12.27%
Enterprise Value	98.73M	PEG	-	EPS next Q	-0.33	Inst Own	22.97%	Short Float	11.83%	Perf Quarter	104.40%
Income	-252.09M	P/S	-	EPS this Y	7.62%	Inst Trans	-7.88%	Short Ratio	5.95	Perf Half Y	115.55%
Sales	0.00M	P/B	1.62	EPS next Y	28.56%	ROA	-80.25%	Short Interest	6.42M	Perf YTD	-82.74%
Book/sh	1.13	P/C	1.36	EPS next 5Y	14.93%	ROE	-89.37%	52W High	17.19 -89.35%	Perf Year	-86.44%
Cash/sh	1.34	P/FCF	-	EPS past 3/5Y	0.69% -	ROIC	-124.38%	52W Low	0.61 199.51%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.93% 7.33%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	9.84%	Oper. Margin	-	ATR (14)	0.13	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.54	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	57.64	Recom	2.50
Dividend Gr. 3/5Y	- -	Current Ratio	10.54	EPS Q/Q	11.67%	SMA20	7.90%	Beta	2.94	Target Price	7.00
Payout	-	Debt/Eq	0.11	Sales Q/Q	-	SMA50	6.89%	Rel Volume	0.66	Prev Close	1.78
Employees	110	LT Debt/Eq	0.11	Earnings	Aug 06 AMC	SMA200	-3.15%	Avg Volume	1.08M	Price	1.83
IPO	Sep 15, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.99% -	Trades		Volume	713,248	Change	2.81%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-16-25	Downgrade	JP Morgan	Neutral → Underweight
Apr-02-25	Downgrade	BofA Securities	Buy → Underperform	$1
Mar-10-25	Downgrade	William Blair	Outperform → Mkt Perform
Mar-07-25	Downgrade	Stifel	Buy → Hold	$6 → $2
Mar-07-25	Downgrade	Guggenheim	Buy → Neutral
Jan-02-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$29 → $4
Nov-05-24	Downgrade	JP Morgan	Overweight → Neutral	$18 → $15
Oct-01-24	Initiated	H.C. Wainwright	Buy	$30
Jul-22-24	Initiated	Needham	Buy	$23
Jul-08-24	Initiated	Mizuho	Outperform	$20
Dec-12-23	Initiated	Deutsche Bank	Hold	$13
Oct-10-23	Initiated	William Blair	Outperform	$26
Oct-10-23	Initiated	Stifel	Buy	$26
Oct-10-23	Initiated	RBC Capital Mkts	Outperform	$24
Oct-10-23	Initiated	JP Morgan	Overweight	$21
Oct-10-23	Initiated	Guggenheim	Buy	$22
Oct-10-23	Initiated	BofA Securities	Buy	$18

Show Previous Ratings

Oct-01-25 07:00AM	Neumora Therapeutics to Host Virtual R&D Day on October 27 (GlobeNewswire)
Sep-17-25 09:40AM	Apple initiated, Hershey upgraded: Wall Streets top analyst calls (TipRanks)
Sep-16-25 09:35AM	Apple initiated, Hershey upgraded: Wall Street's top analyst calls (The Fly)
Sep-02-25 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in September (GlobeNewswire)
Aug-20-25 12:13AM	Neumora Therapeutics Initiates Phase 1 Study for Schizophrenia Drug NMRA-861 (Insider Monkey)
05:07AM	Loading…
Aug-08-25 05:07AM	Elevidys sales weaken; Neumora gets into obesity (BioPharma Dive) -11.52%
Aug-06-25 04:05PM	Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-25 10:23AM	Mizuho Raises Price Target for Neumora (NMRA), Keeps Outperform Rating (Insider Monkey)
Jul-23-25 07:00AM	Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 (GlobeNewswire)
Jul-20-25 12:35AM	Mizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform Rating (Insider Monkey)
Jul-09-25 07:00AM	Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861 (GlobeNewswire) +13.12%
May-13-25 03:10AM	Neumora Therapeutics Inc (NMRA) Q1 2025 Earnings Call Highlights: Advancing Brain Disease ... (GuruFocus.com)
May-12-25 04:01PM	Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-25 07:00AM	Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 (GlobeNewswire)
Apr-22-25 02:49AM	Former Neumora CEO to lead Galapagos spinout (BioPharma Dive) +6.82%
04:10PM	Loading…
Apr-21-25 04:10PM	Galapagos Announces Executive Leadership Updates (GlobeNewswire)
Mar-18-25 05:45AM	Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire)
Mar-07-25 12:26PM	J&J drops Phase III MDD programme due to lack of efficacy (Clinical Trials Arena)
07:08AM	J&J scraps depression testing for potential blockbuster drug (BioPharma Dive)
Mar-04-25 08:30AM	Neumora Therapeutics to Present at Leerink Global Healthcare Conference (GlobeNewswire)
06:25AM	Neumora bids farewell to R&D head; Biohavens one step forward, one step back data (BioPharma Dive)
Mar-03-25 07:00AM	Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -9.94%
Feb-28-25 05:45AM	Shareholders of Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire)
Feb-26-25 08:46PM	Robbins LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors With Large Losses to Contact the Firm to Learn How They Can Recover for Their Losses (PR Newswire)
Feb-25-25 05:45AM	Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire)
Feb-18-25 05:45AM	Investors in Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire)
Feb-13-25 10:33AM	Neumora shakes up its C-suite; Biogen cuts early-stage pipeline (BioPharma Dive)
07:00AM	Neumora Therapeutics Announces Leadership Transition (GlobeNewswire)
Feb-11-25 05:45AM	Investors in Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA (PR Newswire) -6.18%
Jan-04-25 08:00AM	Neumora shares look oversold after 80% drop, says Mizuho (TipRanks)
07:20AM	Loading…
Jan-03-25 07:20AM	Neumora Therapeutics navacaprant did not meet primary endpoint in depression (TipRanks) +10.15%
Jan-02-25 05:07PM	Results are in for a new depression drug trial, and they're cratering this stock (Quartz) -81.42%
04:22PM	Neumora Therapeutics Stock Crashes 81% After Depression Drug Flops (Investor's Business Daily)
01:28PM	Neumora Nosedives 80% At Pre-Market on Failed Depression Drug Trial (Insider Monkey)
01:07PM	Neumora shares sink following Phase III flop in MDD (Pharmaceutical Technology)
12:00PM	Top Stock Movers Now: Uber, Unity Software, Tesla, and More (Investopedia)
10:47AM	Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals (Investopedia)
09:59AM	Stock in Biotech Neumora Plunges 80% as Depression Drug Fails (Barrons.com)
09:54AM	Neumora Plunges After Major Depression Drug Fails in Study (Bloomberg)
08:30AM	Neumora Therapeutics Depression Drug Fails In First Of Three Pivotal Phase 3 Trials (Benzinga)
07:00AM	Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder (GlobeNewswire)
Nov-19-24 08:53AM	Neumora Therapeutics, Inc. (NMRA): This Small-Cap Stock Is Ready To Explode (Insider Monkey)
Nov-12-24 07:00AM	Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -17.08%
Nov-06-24 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in November (GlobeNewswire) +6.72%
Oct-29-24 07:00AM	Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 (GlobeNewswire)
Aug-14-24 07:00AM	Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders (GlobeNewswire)
Aug-06-24 01:54PM	NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q2 2024 (InvestorPlace)
07:00AM	Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-01-24 01:00AM	10 clinical trials to watch in the second half of 2024 (BioPharma Dive)
Jun-20-24 07:00AM	Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation (GlobeNewswire)
May-14-24 08:52AM	Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression (MT Newswires) +6.92%
07:00AM	Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression (GlobeNewswire)
May-07-24 01:54PM	NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024 (InvestorPlace)
10:20AM	Neumora Therapeutics Shares Fall as Q1 Loss Narrows (MT Newswires)
07:00AM	Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-06-24 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in May (GlobeNewswire)
Apr-16-24 11:28AM	Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug (Zacks)
Apr-15-24 04:20PM	Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug (Investor's Business Daily) -17.48%
12:17PM	Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday? (Benzinga)
08:45AM	Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today? (InvestorPlace)
07:47AM	Neumoras schizophrenia drug hit with clinical hold (BioPharma Dive)
06:36AM	U.S. FDA places clinical hold on Neumora's schizophrenia drug study (Reuters)
06:30AM	Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study (GlobeNewswire)
Mar-13-24 07:00AM	Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days (GlobeNewswire) -14.64%
Mar-07-24 02:52PM	NMRA Stock Earnings: Neumora Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jan-22-24 07:00AM	Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer (GlobeNewswire) +9.89%
Jan-10-24 08:32AM	Why Neumora Therapeutics (NMRA) Stock Might be a Great Pick (Zacks)
Jan-02-24 07:00AM	Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-17-23 12:35PM	7 Stocks with Strong Insider Buying: December 2023 (InvestorPlace)
Dec-12-23 07:00AM	Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer (GlobeNewswire)
Nov-27-23 07:00AM	Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study (GlobeNewswire)
Nov-01-23 07:00AM	Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-30-23 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in November (GlobeNewswire) -6.00%
Oct-10-23 07:00AM	Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development (GlobeNewswire) -6.45%
Sep-28-23 07:54PM	Ticking Time Bombs: 3 New Stocks to Dump Before the Damage Is Done (IPO) (InvestorPlace) +11.84% +6.73%
Sep-27-23 06:50PM	Tracking 2023's Largest IPOs: Instacart, Arm, Birkenstock and More (Updated November) (Observer)
Sep-18-23 12:35PM	UPDATE 3-Marketing firm Klaviyo lifts IPO price range, targets $9 bln valuation (Reuters) -8.92%
Sep-14-23 08:49PM	Neumora Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Henry Gosebruch	Officer	Mar 12 '25	Proposed Sale	1.43	15,000	21,450		Mar 12 04:49 PM
BERNS PAUL L	See Remarks	Feb 18 '25	Sale	1.69	13,871	23,468	7,405,004	Feb 20 05:14 PM
Milligan Michael Lee	See Remarks	Feb 18 '25	Sale	1.69	1,978	3,351	22,470	Feb 20 05:14 PM
Aurora Daljit Singh	Chief Strategy Officer	Feb 18 '25	Sale	1.68	8,565	14,347	88,935	Feb 20 05:13 PM
Lenz Robert A.	Head of R&D	Feb 18 '25	Sale	1.67	5,614	9,383	309,092	Feb 20 05:12 PM
Pinto Joshua	President	Feb 18 '25	Sale	1.67	8,048	13,477	76,952	Feb 20 05:11 PM
Suh Carol Y.	Officer	Feb 18 '25	Proposed Sale	1.68	9,540	16,020		Feb 18 05:51 PM
Milligan Michael Lee	Officer	Feb 18 '25	Proposed Sale	1.69	1,978	3,351		Feb 18 05:49 PM
Pinto Joshua	Officer	Feb 18 '25	Proposed Sale	1.67	8,048	13,478		Feb 18 05:45 PM
Lenz Robert A.	Officer	Feb 18 '25	Proposed Sale	1.67	5,614	9,383		Feb 18 05:43 PM
Gosebruch Henry O	Officer	Feb 18 '25	Proposed Sale	1.67	6,857	11,462		Feb 18 05:41 PM
BERNS PAUL L	Officer	Feb 18 '25	Proposed Sale	1.69	13,871	23,468		Feb 18 05:40 PM
Aurora Daljit Singh	Officer	Feb 18 '25	Proposed Sale	1.68	8,565	14,348		Feb 18 05:38 PM
Fust Matthew K	Director	Oct 18 '24	Option Exercise	5.29	14,049	74,309	34,149	Oct 18 06:25 PM
Fust Matthew K	Director	Oct 17 '24	Option Exercise	6.81	7,739	52,730	27,839	Oct 18 06:25 PM
Fust Matthew K	Director	Oct 18 '24	Sale	17.03	14,049	239,319	20,100	Oct 18 06:25 PM
Fust Matthew K	Director	Oct 17 '24	Sale	17.01	7,739	131,643	20,100	Oct 18 06:25 PM
Fust Matthew K	Director	Oct 18 '24	Proposed Sale	17.03	14,049	239,319		Oct 18 04:01 PM
Fust Matthew K	Director	Oct 17 '24	Proposed Sale	17.01	7,739	131,643		Oct 17 04:26 PM
Lenz Robert A.	Head of R&D	Oct 10 '24	Sale	15.09	8,260	124,603	314,706	Oct 11 04:10 PM
Lenz Robert A.	Head of R&D	Oct 09 '24	Sale	15.01	5,563	83,507	322,966	Oct 11 04:10 PM
Lenz Robert A.	Officer	Oct 10 '24	Proposed Sale	15.09	8,260	124,603		Oct 10 04:30 PM
Lenz Robert A.	Officer	Oct 09 '24	Proposed Sale	15.01	5,563	83,507		Oct 09 04:10 PM

Open in Screener

RARE

Ultragenyx Pharmaceutical Inc

Oct 03 • 04:00PM ET

31.21

+0.31 1.00 %

Healthcare • Biotechnology • USA • NASD

RARE Ultragenyx Pharmaceutical Inc daily Stock Chart

Peers: BIIB VRTX ALNY BMRN AMGN REGN IONS CRSP NBIX PBYI

| Held by: VTI XBI VB VBK VXF IWP IBB SCHA IWF IWR

Index	-	P/E	-	EPS (ttm)	-5.53	Insider Own	6.99%	Shs Outstand	96.18M	Perf Week	7.32%
Market Cap	3.01B	Forward P/E	-	EPS next Y	-3.64	Insider Trans	-0.09%	Shs Float	89.64M	Perf Month	-0.22%
Enterprise Value	3.40B	PEG	-	EPS next Q	-1.23	Inst Own	97.75%	Short Float	8.87%	Perf Quarter	-21.21%
Income	-532.93M	P/S	4.93	EPS this Y	20.72%	Inst Trans	4.90%	Short Ratio	3.72	Perf Half Y	-11.16%
Sales	610.16M	P/B	19.84	EPS next Y	26.94%	ROA	-36.44%	Short Interest	7.95M	Perf YTD	-25.81%
Book/sh	1.57	P/C	6.06	EPS next 5Y	45.73%	ROE	-182.60%	52W High	57.99 -46.19%	Perf Year	-44.77%
Cash/sh	5.15	P/FCF	-	EPS past 3/5Y	2.09% 2.45%	ROIC	-55.60%	52W Low	25.81 20.92%	Perf 3Y	-24.38%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	16.82% 40.12%	Gross Margin	79.51%	Volatility	4.25% 3.83%	Perf 5Y	-62.17%
Dividend TTM	-	EV/Sales	5.57	EPS Y/Y TTM	24.18%	Oper. Margin	-82.78%	ATR (14)	1.16	Perf 10Y	-66.84%
Dividend Ex-Date	-	Quick Ratio	2.30	Sales Y/Y TTM	26.77%	Profit Margin	-87.34%	RSI (14)	57.90	Recom	1.19
Dividend Gr. 3/5Y	- -	Current Ratio	2.45	EPS Q/Q	23.19%	SMA20	4.67%	Beta	0.29	Target Price	86.05
Payout	-	Debt/Eq	5.84	Sales Q/Q	13.24%	SMA50	6.22%	Rel Volume	0.64	Prev Close	30.90
Employees	1294	LT Debt/Eq	5.34	Earnings	Aug 05 AMC	SMA200	-13.58%	Avg Volume	2.14M	Price	31.21
IPO	Jan 31, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.81% 2.77%	Trades		Volume	1,363,941	Change	1.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-28-25	Resumed	H.C. Wainwright	Buy	$80
May-28-25	Initiated	William Blair	Outperform
Jun-06-24	Upgrade	Goldman	Neutral → Buy	$56 → $67
Apr-22-24	Initiated	RBC Capital Mkts	Outperform	$77
Dec-08-23	Initiated	Wells Fargo	Overweight	$72
Jun-14-23	Resumed	Credit Suisse	Outperform	$96
Jun-06-23	Upgrade	Evercore ISI	In-line → Outperform	$60 → $80
Apr-26-23	Initiated	Cantor Fitzgerald	Overweight	$114
Jan-18-23	Resumed	Canaccord Genuity	Buy	$90
Dec-30-22	Resumed	H.C. Wainwright	Buy	$82
Nov-03-22	Upgrade	Robert W. Baird	Neutral → Outperform	$50
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy	$50
Aug-01-22	Downgrade	Evercore ISI	Outperform → In-line	$95 → $60
Mar-16-22	Upgrade	Credit Suisse	Neutral → Outperform	$99 → $105
Feb-11-22	Upgrade	JP Morgan	Neutral → Overweight	$132
Sep-30-21	Initiated	H.C. Wainwright	Buy	$106
Aug-19-21	Initiated	UBS	Sell	$73
Jul-15-21	Initiated	Guggenheim	Neutral
Jun-29-21	Upgrade	BofA Securities	Neutral → Buy	$162
Jun-04-21	Resumed	Robert W. Baird	Neutral	$109

Show Previous Ratings

Oct-03-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-02-25 09:45AM	Assenagon Boosts Ultragenyx Pharmaceutical Inc. (RARE) Stake by 439% Amid Breakthrough Pipeline (Insider Monkey)
Sep-30-25 04:05PM	Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President (GlobeNewswire)
04:00AM	Cantor Fitzgerald Reiterates a Buy Rating on Ultragenyx Pharmaceutical (RARE) (Insider Monkey)
Sep-29-25 08:28AM	FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza (Zacks)
04:30PM	Loading…
Sep-19-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-16-25 09:17AM	Is Ultragenyx Pharmaceutical (RARE) a Compelling Long-Term Opportunity? (Insider Monkey)
Sep-10-25 11:11AM	IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome (Zacks)
Sep-09-25 11:12AM	RARE Reports Positive Long-Term Data From Metabolic Disorder Study (Zacks)
Sep-08-25 04:05PM	Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) (GlobeNewswire)
Aug-29-25 04:30PM	Ultragenyx to Participate at Investor Conferences in September (GlobeNewswire) +6.91%
Aug-21-25 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-18-25 08:00AM	Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa) (GlobeNewswire)
Aug-06-25 11:43AM	Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
03:29AM	Ultragenyx Pharmaceutical Inc (RARE) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
05:30PM	Loading…
Aug-05-25 05:30PM	Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
04:06PM	Ultragenyx: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
Aug-04-25 03:32PM	Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory (Insider Monkey)
Jul-31-25 04:05PM	Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome (GlobeNewswire)
11:35AM	Ultragenyx Pharmaceutical Inc. (RARE) Gets FDA CRL for UX111, Vows Quick Resubmission (Insider Monkey)
10:00AM	Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline (Zacks)
Jul-30-25 08:30AM	Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
Jul-24-25 11:09AM	BioHarvest Sciences Inc. (BHST) Surges 5.6%: Is This an Indication of Further Gains? (Zacks)
Jul-22-25 10:05AM	FDA Rejects Replimunes Skin Cancer Treatment, Shares Sink (Bloomberg)
Jul-18-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-17-25 10:38AM	Bank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE) (Insider Monkey)
Jul-16-25 09:38AM	William Blair Maintains a Buy on Ultragenyx Pharmaceutical (RARE) (Insider Monkey)
07:00AM	New Pedestrian Access from Inner Belt to East Somerville MBTA Station Now Open to the Public (PR Newswire)
Jul-15-25 08:28AM	Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA (Zacks) -6.94%
05:46AM	Loading…
05:46AM	Health Canada extends Evkeeza approval for children with HoFH (Pharmaceutical Technology)
Jul-14-25 04:24PM	Ultragenyx Pharma Takes Another Hit As FDA Slaps Its Gene Therapy With A Rejection (Investor's Business Daily)
08:00AM	Health Canada Extends the Approval of Evkeeza (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH) (GlobeNewswire)
07:53AM	FDA rejects Ultragenyx gene therapy over manufacturing concerns (BioPharma Dive)
07:34AM	Ultragenyx receives complete response letter for UX111 BLA (Pharmaceutical Technology)
Jul-13-25 03:12PM	Ultragenyx (RARE) Falls 26% as New Treatment Fails to Get FDA Green Light (Insider Monkey)
Jul-11-25 04:30PM	Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
07:51AM	Jazz names new CEO; Ultragenyx, Mereo shares slide on trial update (BioPharma Dive)
Jul-10-25 04:17PM	Ultragenyx, Mereo Hammered For Their Surprise Miss In Brittle Bone Disease (Investor's Business Daily) -25.11%
10:37AM	Biotech Stock Ultragenyx Is Falling on Unsatisfying Trial Update (Barrons.com)
10:17AM	RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End (Zacks)
09:19AM	Ultragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains? (Zacks)
07:52AM	Kellogg shares soar on buyout talk, and other early market movers (MarketWatch)
Jul-09-25 04:05PM	Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis (GlobeNewswire) +5.12%
12:55AM	Ultragenyx's GTX-102 Receives FDA Breakthrough Therapy Designation for Angelman Syndrome (Insider Monkey)
Jun-30-25 11:40AM	RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome (Zacks)
Jun-27-25 08:00AM	Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome (GlobeNewswire)
Jun-20-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-05-25 11:31AM	Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-03-25 05:00PM	Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-20-25 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.19%
May-14-25 04:30PM	Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report (GlobeNewswire)
May-08-25 10:25AM	Ultragenyx price target lowered to $100 from $140 at Truist (TipRanks) +7.66%
May-07-25 05:00PM	Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference (GlobeNewswire)
12:15PM	Q1 2025 Ultragenyx Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
10:45AM	Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
03:23AM	Ultragenyx Pharmaceutical Inc (RARE) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
May-06-25 11:32PM	Ultragenyx projects $640M-$670M revenue for 2025 with strong product growth (Seeking Alpha) -9.80%
11:31PM	Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:00PM	Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:10PM	Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
May-05-25 09:13AM	5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates (Zacks)
Apr-30-25 05:00PM	Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
Apr-29-25 10:01AM	Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-24-25 10:01AM	Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-22-25 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-21-25 10:00AM	Pz-Cel Has Massive Potential For RDEB Patients (Seeking Alpha)
Apr-16-25 09:49AM	Ultragenyx: Commercial Engine Fuels Rare Disease Pipeline (Seeking Alpha)
Apr-13-25 08:50PM	Ultragenyx Pharmaceutical (RARE): Among Billionaire Stanley Druckenmiller's Top Stock Picks with Huge Upside Potential (Insider Monkey)
Apr-10-25 09:30AM	Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock? (Zacks)
Mar-29-25 04:20PM	Why Ultragenyx Pharmaceutical (RARE) Is Among the Best Mid Cap Biotech Stocks to Buy (Insider Monkey)
Mar-19-25 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-18-25 09:16AM	Ultragenyx price target lowered to $115 from $140 at Piper Sandler (TipRanks)
Feb-24-25 04:30PM	Ultragenyx to Participate at Investor Conferences in March (GlobeNewswire)
Feb-19-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-18-25 08:00AM	Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
Feb-14-25 09:48AM	Q4 2024 Ultragenyx Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
02:23AM	Ultragenyx Pharmaceutical Inc (RARE) Q4 2024 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Feb-13-25 04:19PM	Ultragenyx: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update (GlobeNewswire)
Feb-06-25 04:30PM	Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update (GlobeNewswire)
08:21AM	Ultragenyx announces new data on UX111 AV gene therapy (TipRanks)
Feb-05-25 08:00AM	Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS (GlobeNewswire)
Jan-17-25 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
11:14AM	Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside Potential (Insider Monkey)
Jan-15-25 02:05PM	Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside (Benzinga)
Jan-12-25 11:00AM	Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones (GlobeNewswire)
Jan-06-25 04:30PM	Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
08:07AM	Ultragenyxs Evkeeza secures EU approval for young children with rare cholesterol disorder (Pharmaceutical Technology)
02:00AM	European Commission (EC) Extends the Approval of Evkeeza (evinacumab) to Children as Young as 6-months Old with Homozygous Familial Hypercholesterolemia (HoFH) (GlobeNewswire)
Dec-20-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
03:00AM	NHS England Rolls Out Evkeeza (evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH) (GlobeNewswire)
Dec-19-24 04:05PM	Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome (GlobeNewswire)
08:00AM	Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
Nov-26-24 04:30PM	Ultragenyx to Participate in Investor Conferences in December (GlobeNewswire)
Nov-20-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-09-24 10:30AM	Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science Summit (GlobeNewswire)
Nov-06-24 02:27AM	Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings Call Highlights: Robust Revenue Growth ... (GuruFocus.com)
Nov-05-24 04:11PM	Ultragenyx: Q3 Earnings Snapshot (Associated Press Finance)

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 18 '25	Sale	29.17	64	1,867	50,242	Sep 19 06:23 PM
KARAH PARSCHAUER	Officer	Sep 12 '25	Proposed Sale	31.17	2,450	76,366		Sep 12 04:17 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Sep 12 '25	Sale	31.17	2,450	76,366	73,271	Sep 12 04:11 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 05 '25	Sale	31.39	84	2,637	50,306	Sep 08 02:01 PM
Sanders Corazon (Corsee) D.	Director	Jun 20 '25	Sale	37.39	2,405	89,923	15,344	Jun 23 01:50 PM
CORAZON D. SANDERS	Director	Jun 20 '25	Proposed Sale	37.39	2,405	89,923		Jun 20 04:02 PM
Crombez Eric	EVP and Chief Medical Officer	May 05 '25	Sale	39.24	520	20,405	71,530	May 05 07:18 PM
Crombez Eric	EVP and Chief Medical Officer	Apr 21 '25	Sale	35.11	242	8,497	71,680	May 05 07:18 PM
Horn Howard	Chief Financial Officer	Mar 06 '25	Sale	40.40	1,785	72,114	106,169	Mar 10 12:53 PM
Kassberg Thomas Richard	CBO & EVP	Mar 03 '25	Sale	42.10	6,028	253,779	265,238	Mar 04 08:19 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 03 '25	Sale	42.10	12,846	540,817	75,287	Mar 04 08:18 PM
Crombez Eric	EVP and Chief Medical Officer	Mar 03 '25	Sale	42.10	8,945	376,584	71,922	Mar 04 08:16 PM
Pinion John Richard	See Remarks	Mar 03 '25	Sale	42.10	14,439	607,882	107,766	Mar 04 08:12 PM
KAKKIS EMIL D	President & CEO	Mar 03 '25	Sale	42.10	73,434	3,091,571	641,731	Mar 04 08:10 PM
KAKKIS EMIL D	President & CEO	Feb 28 '25	Sale	42.48	25,000	1,062,000	2,158,985	Mar 04 08:10 PM
Harris Erik	EVP & Chief Commercial Officer	Mar 03 '25	Sale	42.10	15,103	635,836	87,855	Mar 04 08:06 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Mar 03 '25	Sale	42.10	967	40,711	50,265	Mar 04 08:00 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Feb 27 '25	Sale	42.88	2,990	128,224	54,991	Mar 03 01:58 PM
KAKKIS EMIL D	Officer	Feb 28 '25	Proposed Sale	42.48	25,000	1,062,100		Feb 28 04:11 PM
Parschauer Karah Herdman	Officer	Feb 27 '25	Proposed Sale	42.88	2,990	128,215		Feb 27 05:08 PM
KAKKIS EMIL D	President & CEO	Dec 30 '24	Sale	42.23	11,727	495,231	2,183,985	Dec 31 02:05 PM
KAKKIS EMIL D	Officer	Dec 30 '24	Proposed Sale	42.23	11,727	495,264		Dec 30 04:32 PM
KAKKIS EMIL D	President & CEO	Dec 10 '24	Sale	50.00	8,273	413,650	2,195,712	Dec 11 06:44 PM
KAKKIS EMIL D	Officer	Dec 10 '24	Proposed Sale	50.00	8,273	413,650		Dec 10 04:12 PM
Horn Howard	Chief Financial Officer	Oct 10 '24	Sale	52.76	7,465	393,853	92,301	Oct 11 04:48 PM

CRNX

Crinetics Pharmaceuticals Inc

NMRA

Neumora Therapeutics Inc

RARE

Ultragenyx Pharmaceutical Inc

Upgrade your FINVIZ experience